The company will compete by continuing product improvements, ramping up marketing presence, and launching an app to improve doctor and consumer engagement.
Illumina continues to forge partnerships with diagnostic developers overseas as it eyes approximately 50 population sequencing projects around the world.
The subsidiary is the Taiwan-based firm's first and potentially could provide it access to the genetic testing markets in Laos, Cambodia, Vietnam, and Indonesia.
Milu will help launch the test in countries including China as it works to develop a diagnostics business in Asia targeting maternal and women's health.
The company plans to focus on increasing its NIPT reimbursement as well as on pharmaceutical deals for its oncology test and launching a kidney transplantation test.
The firm's fourth quarter preliminary revenues increased by 11 percent to $865 million year over year, while full-year revenues jumped by 21 percent to $3.3 billion.
Researchers tested the combined PGS and PGD assay in a pilot study and now aim to validate it on larger numbers of disorders and compare it to conventional testing.
The company, which changed its name from Premaitha Health last month, saw a 73 percent increase in testing volumes during the first half of fiscal year 2018.
Natera plans to launch its clinical oncology and transplantation tests next year and is hopeful that guidelines endorsing NIPT for average-risk pregnancies are imminent.
The platform, which Waters introduced last month, uses flow-injection tandem mass spectrometry to enable high-throughput analysis of dried blood spots.
During the first year of the TRIDENT-2 study, 74,000 women opted for NIPT, which was switched from in-house-developed platforms to Illumina's VeriSeq in May of this year.
Asuragen's technology will be used in the Early Check study to identify children with rare health conditions, such as fragile X syndrome, before symptoms appear.
